Based on checking the website, Science37.com presents itself as a leader in decentralized clinical trials, aiming to revolutionize how medical research is conducted.

Their core offering, the “Metasite™,” purports to eliminate geographical barriers for patient participation, thereby accelerating trial timelines and enhancing diversity.

This approach directly addresses long-standing challenges in clinical research, such as limited patient access and slow enrollment rates, by enabling patients to participate from virtually anywhere, often from the comfort of their homes.

For anyone tracking the evolution of healthcare and research, Science37.com outlines a compelling vision for a more inclusive and efficient clinical trial ecosystem.

Find detailed reviews on Trustpilot, Reddit, and BBB.org, for software products you can also check Producthunt.

0.0

0.0 out of 5 stars (based on 0 reviews)

Excellent0%

Very good0%

Average0%

Poor0%

Terrible0%

There are no reviews yet. Be the first one to write one.

Amazon.com: Check Amazon for Science37.com Reviews
Latest Discussions & Reviews:

IMPORTANT: We have not personally tested this company’s services. This review is based solely on information provided by the company on their website. For independent, verified user experiences, please refer to trusted sources such as Trustpilot, Reddit, and BBB.org.

Table of Contents

Understanding the Decentralized Clinical Trial DCT Model

Think of it like this: traditional trials are rigid, requiring patients to travel to specific physical sites, often far from home, for every visit.

This creates significant barriers to participation, particularly for individuals in rural areas, those with mobility issues, or those with demanding schedules.

Science37.com’s “Metasite™” concept aims to tear down these walls, operating as a “site without borders.”

What is a Decentralized Clinical Trial?

A decentralized clinical trial is a clinical trial conducted either entirely or in part remotely, leveraging technology to connect with patients.

Instead of requiring patients to visit a physical research site for all study-related activities, DCTs use tools like telemedicine, mobile healthcare providers, wearable devices, and e-Consent platforms to enable participation from a patient’s home or a local, convenient setting. Timetaco.com Reviews

The goal is to make research more accessible, patient-centric, and efficient.

This model significantly broadens the potential pool of participants, moving beyond the 8% of the population typically able to participate in traditional site-based research.

How Science37.com Implements the DCT Model

Science37.com positions its Metasite™ as the vehicle for delivering these remote trials.

Their implementation involves a combination of proprietary technology and a network of medical experts.

They leverage a unified platform that guides the workflow for patients and study staff, ensuring compliance and high-quality data collection. Interval-timer.com Reviews

This platform integrates various components like eSource, eCOA Clinical Outcome Assessments, ePRO Patient-Reported Outcomes, eDiary, and connected devices, all designed to capture data without manual re-entry.

This centralized approach of “people, processes, and platform” is touted as the key to built-in protocol compliance and a seamless patient journey.

Benefits of the Metasite™ Approach

The website highlights several key benefits of their Metasite™ model, backed by impressive statistics:

Increased Population Reach: Science37 claims 100% population reach compared to less than 8% for traditional site-based trials. This means they can tap into a much larger, more diverse patient pool.
Faster Start-Up Times: They boast 2X faster start-up times, with the ability to launch nationwide in a single day. This efficiency can significantly reduce the overall time to bring new treatments to market.
Greater Diversity: The Metasite™ model allegedly leads to 3X greater diversity in patient populations, addressing a critical need in clinical research where traditional trials often lack representation from various demographic groups traditional diversity is cited at 14%.
Higher Patient Retention: Science37 reports an impressive 96% patient retention rate, compared to a traditional 70%. This is crucial as patient drop-off can severely impact trial integrity and timelines.

These figures, if consistently achieved, represent a significant leap forward in trial efficiency and inclusivity, potentially de-risking the entire research process for sponsors.

Science37.com’s Proprietary Unified Platform

At the heart of Science37.com’s decentralized model lies its proprietary unified platform. This isn’t just a collection of apps. Blockhero.com Reviews

It’s presented as a comprehensive ecosystem designed to orchestrate every aspect of a clinical trial remotely.

For anyone considering engaging with Science37, understanding the depth and breadth of this platform is critical, as it underpins their entire operational strategy.

Components and Functionality of the Platform

The Science37 platform is depicted as a central nervous system for remote trials, ensuring that data is collected accurately, consistently, and compliantly. Key functionalities include:

eConsent: Streamlining the informed consent process digitally, making it more accessible and manageable for patients.
eSource: Direct electronic data capture, reducing the need for manual transcription and minimizing errors.
eCOA Clinical Outcome Assessments, ePRO Patient-Reported Outcomes, eDiary: Tools for patients to report symptoms, experiences, and data directly, often through their own devices. This allows for real-time data capture and reduces recall bias.
Connected Devices Integration: Ability to integrate data from wearables and other connected health devices, providing objective, continuous measurements of vital signs, activity levels, and other health parameters.
Workflow Orchestration: Guides both patients and study staff investigators, nurses, coordinators through their respective tasks, ensuring protocol adherence and timely execution.
Data Centralization: All collected data is centralized within the platform, eliminating the need for manual re-entry and streamlining data analysis.

This integrated approach aims to create a “built-in protocol compliance” mechanism, ensuring that all activities align with Good Clinical Practice GCP standards.

Ensuring Compliance and Data Quality

The website emphasizes that the unified platform is “compliant by nature.” This is a bold claim, but it speaks to the fundamental design philosophy. Parsley-health.com Reviews

By centralizing people, processes, and technology, Science37 aims to achieve:

Unified Journey: A consistent experience for patients and staff, minimizing variations that could impact data quality.
Greater Compliance: Automated workflows and integrated checks designed to ensure adherence to study protocols and regulatory requirements.
High-Quality Data: Direct data capture from eSource, ePRO, and connected devices reduces human error and provides richer, more accurate datasets.

The platform’s design appears to be a direct response to the inherent challenges of remote data collection, where maintaining data integrity and regulatory compliance is paramount.

For sponsors, the promise of higher data quality and inherent compliance is a significant draw, potentially de-risking the entire trial.

Clinical Expertise and Therapeutic Area Coverage

A cutting-edge platform is only as good as the clinical expertise behind it.

Science37.com highlights its robust network of in-house medical experts, emphasizing their extensive experience in remote trial conduct. Mightyscout.com Reviews

This aspect is crucial for instilling confidence in potential partners, as the nuances of different therapeutic areas demand specialized knowledge.

In-House Medical Teams and Specialties

Science37.com asserts it possesses “medical experts with the most experience in remote trial conduct.” This includes a diverse array of specialists, from oncologists to CNS physicians. Their in-house teams comprise:

Telemedicine Investigators: Physicians licensed across multiple states and countries, capable of conducting remote patient consultations, assessments, and follow-ups.
Mobile Nurses: A network of nurses who can conduct in-home visits for procedures requiring physical presence, such as blood draws, vital sign measurements, or drug administration.
Specialized Physicians: Experts across a broad spectrum of therapeutic areas, ensuring that the nuances of specific diseases are understood and managed appropriately within a decentralized framework.

The website lists several key therapeutic areas they cover, indicating a broad capability:

Infectious Disease
Endocrinology
Dermatology
Cardiology
Central Nervous System CNS
Rare Disease
Oncology
Respiratory

This breadth of coverage suggests Science37 aims to be a versatile partner for pharmaceutical companies and CROs across various medical disciplines.

Ensuring Patient Safety and Scientific Integrity GCP Standards

In any clinical trial, patient safety and data integrity are non-negotiable. Privacyangel.com Reviews

Science37.com explicitly states that “Good Clinical Practice GCP standards are of the utmost importance,” with the Metasite™ built to ensure safety and high scientific integrity. This means:

Robust Monitoring: Even in a remote setting, monitoring processes must be in place to ensure patient well-being and data accuracy. This likely involves remote monitoring of data, telemedicine consultations, and potentially in-home visits by mobile nurses.
Adverse Event Reporting: Clear protocols for identifying, reporting, and managing adverse events, regardless of where the patient is located.
Ethical Review: All trial protocols must undergo rigorous ethical review board IRB/EC approval, and Science37’s model must facilitate this process even in a decentralized context.
Investigator Oversight: Remote investigators must maintain appropriate oversight of their patients and study activities, leveraging the platform to do so effectively.

The promise of maintaining GCP standards within a decentralized framework is a significant differentiator.

It suggests that Science37 has invested heavily in the infrastructure and processes required to meet stringent regulatory expectations, which is paramount for any credible clinical research organization.

The Science37 Metasite™ in Action: Delivering Trial Activities

The true test of any innovative clinical trial model is its ability to execute the full spectrum of necessary activities effectively.

Science37.com showcases how its Metasite™ is designed to manage everything from initial patient engagement to endpoint data collection, ensuring a comprehensive and flexible approach. Traveloffers.com Reviews

This demonstrates their capability to handle the complexities of a clinical trial from end-to-end within a decentralized framework.

Comprehensive Trial Activity Coverage

The website details a wide array of trial activities that the Metasite™ can deliver, illustrating its versatility:

Patient Recruitment: Leveraging a wider reach to find eligible participants who might otherwise be unable to join traditional trials.
Patient Engagement / Retention: Utilizing digital tools and flexible participation options to keep patients motivated and involved throughout the study, contributing to their high retention rates.
Screening & Enrollment: Conducting eligibility assessments and the enrollment process remotely, making it more convenient for potential participants.
Onboarding eConsent: Facilitating the informed consent process digitally, which improves efficiency and patient understanding.
Study Activities: Managing day-to-day study tasks, data collection, and patient interactions through the unified platform.
Endpoint Data Collection: Capturing critical outcome data through various digital means, including eSource, eCOA, ePRO, eDiary, and connected devices.
Labs, Vitals, and Medications: Orchestrating the collection of biological samples, vital sign measurements, and medication distribution, often through mobile healthcare providers or local clinics.
Study Management: Overseeing the overall trial progress, data quality, and regulatory compliance remotely.
Study Visits Telemedicine, Mobile Healthcare, Community Clinics: Offering flexible options for patient interactions, including virtual visits, in-home nurse visits, and collaborations with local healthcare providers for specific procedures.

This extensive list highlights that Science37 isn’t just offering a piecemeal solution but a holistic approach to decentralized trial conduct.

Real-World Case Studies and Testimonials

To underscore their capabilities, Science37.com features several case studies that provide concrete examples of the Metasite™ in action:

Infectious Disease Study: A case study demonstrating how Science37 accelerated timelines and expanded reach in an infectious disease trial. This is particularly relevant in the post-pandemic era where rapid deployment of research is critical.
MDD Major Depressive Disorder Trial: Showcasing how their decentralized model delivered results in MDD through centralized enrollment, indicating their ability to manage complex CNS studies remotely.
Rare Neurodegenerative Disease Study: A hybrid clinical trial where Science37 supported a rare disease, highlighting their flexibility and ability to adapt to unique study requirements.
Flexible Model Utilization: Another case study demonstrating how the Metasite™ model’s flexibility was utilized in a general study, emphasizing its adaptability across various therapeutic areas.

Beyond case studies, the website includes testimonials from industry players like IDC, GlobalData, and anonymous clinical trial sponsors. Xpressit.com Reviews

These quotes reinforce the benefits of Science37’s model, praising its ability to complement conventional sites, emphasize training for accurate data collection, prioritize patient preference, and enroll diverse populations.

For instance, one sponsor noted, “Science 37 allows us to enroll patients who don’t traditionally participate in trials, decreasing burden on patients and site, improving diversity and reach.” These endorsements provide real-world validation of their claims.

Benefits for Stakeholders: Participants, Sponsors, HCPs, and CROs

Science37.com emphasizes that its Metasite™ model works for everyone involved in the clinical research ecosystem.

This multi-stakeholder benefit proposition is a key selling point, as it addresses the diverse needs and pain points of trial participants, sponsors, healthcare professionals, and Contract Research Organizations CROs. Understanding these specific advantages helps to clarify the widespread appeal of the decentralized approach.

Advantages for Trial Participants

For patients, the Metasite™ model promises a significant improvement in convenience and access, which are often major hurdles to participation: Tourscanner.com Reviews

Access to Trials Regardless of Site Proximity: Patients are no longer limited by geographical location, opening up opportunities for individuals in remote areas or those without easy access to major medical centers.
Participation from the Comfort of Home: Many study activities can be conducted virtually or through mobile healthcare, reducing the need for travel, time off work, and childcare arrangements.
Flexible Participation: The model accommodates patients’ schedules and preferences, making it easier to integrate trial activities into their daily lives. This patient-centricity is a major draw, potentially leading to higher satisfaction and retention rates.
Reduced Burden: Less travel means less time, expense, and stress, significantly improving the overall patient experience.

Advantages for Sponsors

Pharmaceutical and biotechnology companies Sponsors stand to gain substantially from Science37’s model, primarily through enhanced efficiency and broader reach:

Speed: Accelerating recruitment and overall trial timelines due to a larger, more accessible patient pool. As cited on their site, this can lead to “2X Faster Start Up Times.”
Diversity: Achieving greater patient diversity e.g., “3X Greater Diversity” is crucial for developing treatments that are effective across different populations and meeting regulatory expectations.
Patient-Centricity: A patient-friendly model can lead to higher engagement and retention rates, which are critical for trial success and data completeness.
Greater Compliance and High-Quality Data: The unified platform and structured workflows are designed to ensure protocol adherence and accurate data collection, mitigating risks for sponsors.
Expanded Access Globally: The model supports patient recruitment in remote locations and underrepresented communities, complementing traditional site mixes and addressing global health disparities.

Advantages for Healthcare Professionals HCPs

HCPs, including physicians and nurses, also find distinct benefits in collaborating with Science37:

Provide Clinical Research as a Care Option: For many HCPs, offering clinical trials is a way to provide cutting-edge treatment options to their patients, even if their practice isn’t a dedicated research site.
Manage Patients Remotely with Flexible Hours: The telemedicine component allows HCPs to oversee trial patients with greater flexibility, potentially integrating research activities into their existing practice more seamlessly without disrupting their primary patient care responsibilities.
Reduced Administrative Burden: The platform’s integrated workflow can streamline data entry and compliance, freeing up HCPs to focus more on patient care.

Advantages for Contract Research Organizations CROs

CROs, which often manage clinical trials on behalf of sponsors, can leverage Science37’s model to enhance their offerings:

Unique Site Model: The Metasite™ provides a distinct and innovative approach to trial execution that CROs can offer to their clients.
Mitigate Enrollment Risk: By expanding access to a wider patient population, CROs can reduce the risk of under-enrollment, a common challenge in traditional trials.
Expand as Necessary Based on Study Performance: The flexible nature of the decentralized model allows for scaling up or down based on the specific needs and performance of a study, offering greater adaptability.

The Science37 Model’s Impact on Diversity and Inclusivity

One of the most compelling aspects of Science37.com’s Metasite™ model is its significant potential to enhance diversity and inclusivity in clinical trials.

Traditional site-based trials have historically struggled with recruiting diverse patient populations, leading to medical innovations that may not be equally effective or safe for all demographic groups. Shelly.com Reviews

Science37’s approach directly targets this long-standing issue.

Addressing Health Disparities Through Decentralization

Clinical research has a documented history of underrepresentation among certain racial, ethnic, geographic, and socioeconomic groups. This can lead to:

Limited Generalizability: Study results may not accurately reflect how a treatment will work in the broader population.
Missed Safety Signals: Adverse events unique to certain demographic groups might go undetected.
Exacerbated Health Disparities: Treatments developed based on homogenous trial populations may not be optimal for diverse patient needs.

Science37’s decentralized model directly addresses these disparities by removing the most common barriers to participation:

Geographic Barriers: Eliminating the need to travel to distant urban medical centers opens up trials to rural populations.
Socioeconomic Barriers: Reducing travel costs, time off work, and childcare needs makes participation feasible for individuals with fewer resources.
Mobility Barriers: Patients with physical disabilities or chronic conditions can participate from their homes.

Statistics on Enhanced Diversity

The website explicitly quantifies its impact on diversity, stating: “3X Greater Diversity” compared to traditional site-based trials which they cite as 14%. While specific breakdown of this diversity e.g., racial, ethnic, age, socioeconomic isn’t detailed on the homepage, the implication is a significant improvement across various demographic factors.

Achieving greater diversity is not just an ethical imperative. it’s also a scientific and regulatory one. Crocoblock.com Reviews

Regulatory bodies like the FDA in the United States are increasingly emphasizing the need for diverse trial populations to ensure drug efficacy and safety across all potential users.

Broader Implications for Research Equity

The move towards decentralized trials, championed by companies like Science37, has broader implications for research equity:

Community Engagement: By bringing trials directly to patients’ communities or their homes, it can foster greater trust and engagement with clinical research, especially in historically underserved populations.
Real-World Data: Participating from their natural environment can provide more real-world data, reflecting how treatments are used and experienced in daily life, rather than in a highly controlled, artificial clinical setting.
Patient Empowerment: Giving patients more control over their participation, including where and when they engage, can lead to a more empowering research experience.

Ultimately, Science37.com’s focus on diversity and inclusivity is a powerful testament to the transformative potential of decentralized clinical trials, moving beyond mere efficiency gains to create a more representative and equitable future for medical science.

Comparative Advantages Over Traditional Clinical Trial Models

When evaluating Science37.com, it’s essential to understand its distinct advantages over the long-standing traditional clinical trial model. This isn’t just about incremental improvements.

It’s about a fundamental shift in approach that addresses systemic inefficiencies and limitations. Unibui.com Reviews

While traditional sites have their place, Science37’s decentralized methodology offers compelling benefits in speed, reach, and patient experience.

Overcoming Limitations of Traditional Site-Based Trials

Traditional clinical trials are typically conducted at centralized research sites, such as hospitals, academic medical centers, or dedicated research clinics.

While these sites offer controlled environments and direct oversight, they come with significant drawbacks:

Geographical Constraints: Patients must live within a reasonable commuting distance of the site, severely limiting the recruitment pool.
Time Burden for Patients: Frequent in-person visits require patients to take time off work, arrange transportation, and potentially childcare, leading to high dropout rates.
Limited Diversity: The recruitment pool is often biased towards urban populations and those with the resources to travel, leading to underrepresentation of diverse demographics.
Slow Recruitment: Identifying and enrolling eligible patients can be a protracted process, often delaying trial timelines. According to industry data, up to 85% of clinical trials experience delays due to patient recruitment challenges, and nearly 20% fail to enroll a single patient.
High Operational Costs: Maintaining physical sites, staffing, and managing logistics for in-person visits can be expensive.

How Science37.com’s Metasite™ Provides Solutions

The Metasite™ model directly counteracts these traditional limitations:

Expanded Access: By removing physical proximity as a barrier, Science37 boasts “100% Population Reach,” enabling recruitment from a vastly larger and more varied pool. This directly addresses the ~8% participation rate in traditional trials.
Accelerated Timelines: With “2X Faster Start Up Times” and enhanced recruitment capabilities, the overall duration of a trial can be significantly reduced. This is a critical factor for pharmaceutical companies looking to bring treatments to market faster.
Improved Patient Experience & Retention: The flexibility to participate from home or local clinics significantly reduces patient burden. This leads to higher satisfaction and, importantly, a 96% patient retention rate compared to ~70% in traditional trials, ensuring more complete data sets.
Enhanced Diversity: As discussed, the model’s inherent accessibility leads to “3X Greater Diversity,” addressing a crucial need for representative research.
Uniform Study Conduct: While decentralized, the proprietary platform ensures consistent protocol adherence and data collection across all participants, maintaining scientific rigor. This contrasts with potential site-to-site variability in multi-site traditional trials.
Reduced Operational Complexities for Sponsors/CROs: Consolidating “the recruiting power of 20 sites in one” and streamlining workflows through a unified platform can simplify trial management and potentially reduce certain overheads associated with managing numerous physical sites.

In essence, Science37.com offers a scalable, patient-centric alternative that leverages technology to overcome the geographical and logistical hurdles that have long plagued traditional clinical research. Eventvalue.com Reviews

This positions them as a strategic partner for organizations seeking to modernize and accelerate their clinical development programs.

Future Outlook and Market Position of Decentralized Trials

The emergence and rapid adoption of decentralized clinical trials, heavily influenced by companies like Science37.com, are not just a temporary trend.

They represent a significant evolutionary step in clinical research.

Understanding the market position and future outlook of DCTs provides context for Science37’s role and potential impact.

Growth Trajectory of the DCT Market

The COVID-19 pandemic acted as a major catalyst for the adoption of DCTs, forcing a rapid pivot to remote methodologies. Wegacha.com Reviews

What started as a necessity has now become a preferred strategic approach for many sponsors.

Industry reports consistently project substantial growth in the DCT market:

Estimates suggest the global decentralized clinical trials market size was valued at USD 10.4 billion in 2022 and is projected to grow at a Compound Annual Growth Rate CAGR of over 14% from 2023 to 2030, reaching potentially USD 30 billion by 2030. Source: Grand View Research, Fortune Business Insights, etc., various reports consistently show strong growth.
A recent survey by Tufts Center for the Study of Drug Development CSDD found that over 70% of sponsors expect to increase their use of decentralized trials in the coming years.

This robust growth is driven by the clear benefits discussed, such as accelerated timelines, reduced costs, enhanced patient access, and improved diversity, all of which contribute to a more efficient drug development process.

Science37.com’s Position in the DCT Landscape

Science37.com positions itself as a specialized “Metasite™” provider, distinct from CROs that might offer DCT services as one of many offerings. Their focus appears to be on being the solution for fully decentralized or hybrid trials, rather than a full-service CRO. This specialization allows them to refine their proprietary platform and clinical expertise specifically for remote conduct.

Niche Specialization: By focusing on the “site without borders” concept, Science37 has carved out a unique niche. They are not merely providing DCT components but a complete, integrated site model that is virtual.
Proprietary Technology: Their unified platform is a key differentiator, promising seamless integration and compliance, which can be a competitive advantage over competitors relying on disparate third-party tools.
Strategic Partnerships: Testimonials from IDC and GlobalData, as well as unnamed sponsors, suggest they are gaining traction with major industry players, indicating strong market acceptance. The quote, “Science 37 Metasite™ strategy complements the conventional site mix,” suggests they are seen as an additive rather than a replacement to traditional research.

Challenges and Future Directions

Despite the promising outlook, the DCT market and Science37 will face challenges: Coinlib.com Reviews

Technology Integration Complexity: Ensuring seamless integration of various devices and software, as well as robust cybersecurity, remains an ongoing task.
Patient Digital Literacy: While broader access is a benefit, ensuring all participants are comfortable and capable of using digital tools is crucial.
Hybrid Models: The future likely involves more hybrid models, combining elements of traditional and decentralized approaches, requiring flexibility from providers like Science37 to integrate effectively.

Science37.com’s future success hinges on its ability to continue innovating its platform, expand its global reach, and maintain its high standards of compliance and patient safety as the DCT market matures.

Their focus on accessibility and diversity aligns well with the broader societal and scientific imperative for more inclusive medical research, suggesting a strong trajectory for the years to come.

Frequently Asked Questions

Is Science37.com a legitimate company?

Yes, based on checking the website, Science37.com presents itself as a legitimate company specializing in decentralized clinical trials, with published case studies and testimonials from industry analysts and sponsors.

What is Science37.com’s main service?

Science37.com’s main service is providing a “Metasite™” model for decentralized clinical trials, enabling patients to participate in medical research remotely, from anywhere.

How does Science37.com help with patient recruitment?

Science37.com claims to expand patient access significantly by removing geographical barriers, allowing for 100% population reach, thereby accelerating patient recruitment compared to traditional site-based trials.

What therapeutic areas does Science37.com cover?

Science37.com states it covers a wide range of therapeutic areas, including Infectious Disease, Endocrinology, Dermatology, Cardiology, Central Nervous System, Rare Disease, Oncology, and Respiratory.

Does Science37.com use telemedicine?

Yes, Science37.com explicitly mentions the use of telemedicine investigators and experts as a core component of their decentralized trial model to facilitate remote patient interactions.

What is the Science37.com unified platform?

The Science37.com unified platform is a proprietary technology designed to orchestrate all aspects of a decentralized clinical trial, guiding workflows for patients and staff, and capturing high-quality data without manual re-entry.

How does Science37.com ensure data quality and compliance?

Science37.com states its unified platform is “compliant by nature,” driving uniform study orchestration, ensuring greater compliance, and capturing high-quality data through integrated eSource, eCOA, ePRO, and connected devices.

What is eConsent and does Science37.com use it?

Yes, eConsent is electronic informed consent, and Science37.com uses it as part of its onboarding process to make patient consent more efficient and accessible remotely.

Does Science37.com offer in-home nursing visits?

Yes, Science37.com mentions utilizing mobile nurses as part of their model to deliver certain trial activities, such as labs, vitals, and medications, at a patient’s home.

How does Science37.com improve trial diversity?

Science37.com claims their decentralized model leads to “3X Greater Diversity” in patient populations by expanding access beyond traditional site limitations, reaching underrepresented communities.

Is Science37.com suitable for rare disease trials?

Yes, Science37.com features a case study supporting a hybrid clinical trial in a rare neurodegenerative disease, indicating their model’s suitability for rare disease research.

What are the benefits for trial participants using Science37.com?

For trial participants, benefits include gaining access to trials regardless of site proximity, participating from home, and experiencing reduced burden due to flexible participation options.

How does Science37.com benefit clinical trial sponsors?

Sponsors benefit from increased speed, greater diversity, enhanced patient-centricity, higher compliance, and high-quality data, as well as expanded access to patient populations globally.

Can Contract Research Organizations CROs partner with Science37.com?

Yes, Science37.com highlights benefits for CROs, stating their model can set up a unique site model that mitigates enrollment risk and expands based on study performance.

Does Science37.com comply with GCP standards?

Yes, Science37.com explicitly states that “Good Clinical Practice GCP standards are of the utmost importance,” and their Metasite™ is built to ensure safety and high scientific integrity.

What is the patient retention rate for Science37.com trials?

Science37.com reports an impressive 96% patient retention rate for their trials, significantly higher than the traditional 70% retention rate.

How does Science37.com accelerate trial timelines?

Science37.com claims to accelerate timelines through faster start-up times 2X faster and efficient patient recruitment enabled by their widespread population reach.

Are there case studies available for Science37.com’s work?

Yes, the website features several case studies demonstrating the Metasite™ in action across various therapeutic areas like infectious disease, MDD, and rare neurodegenerative diseases.

Does Science37.com support global clinical trials?

Yes, Science37.com indicates that their model helps sponsors and CROs expand access to clinical trials globally, suggesting capabilities for international operations.

How can I learn more about Science37.com’s services?

The Science37.com website provides contact information and a “Connect with a Science 37 Solutions Expert Today” call to action for further inquiries.

Science37.com Reviews